

JUL 22 1998
Date of Approval: _____

FREEDOM OF INFORMATION (FOI) SUMMARY

EtoGesic™ (etodolac) Tablets for Dogs

NADA 141-108

Fort Dodge Animal Health
Cyanamid Agricultural Research Center
P.O. Box 400
Princeton, New Jersey 08543-0400

NADA 141-108

FOIS 1

FREEDOM OF INFORMATION SUMMARY

EtoGesic™ Tablets for Dogs

NADA 141-108

TABLE OF CONTENTS

I.	General Information	Page 2
II.	Indication For Use	Page 2
III.	Dosage Form, Route of Administration and Recommended Dosage	Page 2
IV.	Effectiveness	Page 3
	Dose Determination and Clinical Field Study (P440-C2)	Page 3
V.	Target Animal Safety Studies	Page 6
	1. AY-24,236: Etodolic Acid One-Year Oral Toxicity Study - Dog	Page 7
	2. AY-24,236: Etodolic Acid Six-Month Oral Toxicity - Dog	Page 9
	3. Study P440-C6	Page 11
VI.	Pharmacokinetics and Bioavailability	Page 13
	1. Three-Way Oral Tablet and Oral Gavage Crossover Bioavailability Study with Etodolac in Dogs (P440-C7)	Page 13
	2. Pharmacokinetics in Dogs with Reduced Kidney Function	Page 14
VII.	Human Safety	Page 16
VIII.	Agency Conclusions	Page 16
IX.	Labeling	Attached

FREEDOM OF INFORMATION SUMMARY

EtoGesic™ Tablets for Dogs

NADA 141-108

I. General Information

- A. NADA Number: 141-108
- B. Sponsor: Fort Dodge Animal Health
Cyanamid Agricultural Research Center
P.O. Box 400
Princeton, New Jersey 08543-0400
- C. Generic Name: Etodolac
- D. Tradename: EtoGesic™
- E. Marketing Status: Rx

II. Indication For Use:

Etodolac is recommended for the management of pain and inflammation associated with osteoarthritis in dogs.

III. Dosage Form, Route of Administration and Recommended Dosage:

Dosage Form: Etodolac is a biconvex, half-scored tablet that contains 150 or 300 mg of etodolac.

Route of Administration: The product is designed to be administered orally.

Recommended Dosage: The recommended dose of EtoGesic™ tablets for dogs is 10 to 15 mg/kg body weight (4.5 to 6.8 mg/lb) given orally once daily.

IV. Effectiveness

A study was conducted in dogs to demonstrate the efficacy of EtoGesic™ (etodolac) for the management of pain and inflammation associated with osteoarthritis. This combined dose determination and clinical field trial was conducted in four geographically distinct locations by four veterinary orthopedic specialists. The safety of etodolac in the field was also assessed. Results of this study demonstrated that etodolac is efficacious when administered at a daily dose of approximately 15 mg/kg body weight for 8 days.

Dose Determination and Clinical Field Study (P440-C2)

a. Type of Study: Combined Dose Determination and Clinical Field Study

b. Investigators:

Name and Location	Cases
Dr. Steven Budsberg Department of Small Animal Medicine and Surgery University of Georgia Athens, GA 30602	22
Dr. Charles DeCamp Department of Small Animal Clinical Sciences Michigan State University East Lansing, MI 48824	20
Dr. Spencer Johnston Department of Small Animal Clinical Sciences Virginia Polytechnic Institute and State University Blacksburg, VA 24061	38
Dr. Peter Schwarz Department of Veterinary Clinical Sciences Colorado State University Fort Collins, CO 80523	36

c. General Design

- i. Purpose: The study was conducted to determine an effective dose for EtoGesic™ tablets in dogs with osteoarthritis associated with chronic hip dysplasia.
- ii. Test Animals: One hundred sixteen client-owned dogs from four separate locations entered the study. The dogs were of various

breeds, ranged in weight from 26 to 43 kg (57 to 95 lb), and were 1 to 10 years of age. A total of 100 dogs completed the study and were used in the statistical analysis. Sixteen additional dogs received the drug for at least part of the dosing regimen, however, they were not utilized in the analysis for efficacy due to protocol deviations. Young, 1-3 year old, fast growing, giant breeds of dogs and obese chondrodysplastic dogs within the acceptable age and weight ranges were excluded from the study. Dogs were limited to the weight range listed above in order to reduce variables in force plate evaluations.

- iii. Placebo Control: Treatment with tablets similar to the proposed market formulation except for the absence of active ingredient.
- iv. Diagnosis: Dogs had at least a six-month history of chronic hip dysplasia, were free of confounding diseases, and presented with clinical signs such as lameness or pain. Radiographs were used to confirm the diagnosis of hip dysplasia.
- v. Dosage Form: The tablets were identical to the proposed market formulation.
- vi. Route of Administration: Oral.
- vii. Dosages used: 135 mg/day to provide approximately 4.5 mg/kg/day (2.0 mg/lb/day) and 450 mg/day to provide approximately 15 mg/kg/day (6.8 mg/lb/day). Actual doses administered to the 450 mg/day group ranged from 11.0 to 17.6 mg/kg/day.
- viii. Treatment Duration: 8 days.
- ix. Parameters Measured: Mobility was evaluated twice before the start of therapy and once at the end of therapy by force plate analysis. Prescreening force plate evaluations were performed twice within 5 to 10 days prior to study entry to establish baseline values. The percent difference between mean values of the two force plate vertical impulse area measures taken prior to admission was required to be $\leq 15\%$ for a patient to enter the study. Mobility was also assessed at these times by limb disuse, pain on palpation, and weight bearing scores by a qualified veterinarian.

General health was evaluated by physical examinations performed at one week before treatment, just prior to treatment initiation, and at the end of therapy. Samples for serum chemistry, hematology, urinalysis, and fecal parasite analyses were collected before and at the end of treatment.

- d. Results: When measured objectively as vertical impulse area by force plate technology, etodolac treatment was associated with an increase in the amount of weight carried. Dogs receiving either dose of etodolac exhibited statistically significant increases in vertical impulse area relative to pretreatment values, while only slight improvement was experienced by controls (Table 1). Moreover, the increase in vertical impulse area among dogs receiving the 450 mg dose of etodolac was significantly greater than the corresponding change among controls. The higher dose produced greater improvement in this parameter than did the lower dose.

Table 1. Effect of etodolac therapy on mobility as measured by force plate analysis.¹

Parameter	Daily Dose of Etodolac		
	Placebo	135 mg	450 mg
Vertical impulse area	0.04	0.13 ^b	0.22 ^{a,b}

¹Values are expressed as change from average pretreatment values in units of 100 x N x sec/kg BW for impulse area of the most affected rear leg.

^aSignificantly improved compared to placebo (P < 0.05).

^bSignificantly improved from pretreatment (P < 0.05).

After therapy with either dose of etodolac, significant improvements were found for all subjective measurements of mobility, i.e. limb disuse, pain on palpation, and weight bearing. Significant improvement was also found among controls.

- e. Statistical Analysis: Force plate data were analyzed by mixed model analysis of covariance using the average pretreatment values as the covariate. Treatment groups were compared using least square means. All tests were one-sided and conducted at the 0.05 level.

- f. **Conclusions:** This study demonstrated that etodolac administered at a dose of approximately 15 mg/kg/day for 8 days is effective for management of signs associated with osteoarthritis secondary to hip dysplasia in dogs. Etodolac at a dose of 4.5 mg/kg/day provided suboptimal efficacy. This study also demonstrated the safety of etodolac administered at a dose of 15 mg/kg once a day for 8 days under field conditions.
- g. **Adverse Reactions:** Three dogs developed hypoproteinemia during the course of etodolac therapy. One dog was diagnosed with a pre-existing intestinal lymphosarcoma by the Clinical Investigator, and the hypoproteinemia was attributed to this disease. In the two other dogs, the hypoproteinemia resolved after treatment ended.

Other than the hypoproteinemia detailed above, samples collected for clinical pathology showed no statistically significant, dose-dependent changes outside normal physiological ranges in any serum chemistry, hematology, or urinalysis parameters ($P > 0.10$).

Adverse reactions reported during the field trial are tabulated below.

Table 2. Adverse reaction reported during Study P440-C2 (number of dogs = 116).

Adverse Reaction	EtoGesic % of dogs	Placebo % of dogs
vomiting	4.3%	1.7%
regurgitation	0.9%	2.6%
lethargy	3.4%	2.6%
diarrhea / loose stool	2.6%	1.7%
hypoproteinemia	2.6%	0
urticaria	0.9%	0
behavioral change, urinating in house	0.9%	0
inappetance	0.9%	1.7%

V. Target Animal Safety Studies

Two studies investigated the effects of continuous once daily oral administration of etodolac tablets to adult dogs over a period of six months at dosages up to 90 mg/kg body weight and one year at dosages up to 80 mg/kg body weight.

These studies show that the primary adverse effect of etodolac is gastrointestinal toxicity.

1. AY-24,236: Etodolic Acid One-Year Oral Toxicity Study - Dog

a. Type of Study: One Year Oral Toxicity

b. Investigator: Dr. R. D. Hemm
Ayerst Research Laboratories
Chazy, NY 12921

c. General Design

i. Purpose: To determine the toxicological effects of oral doses of etodolac given once daily for one year.

ii. Test Animals: Sixteen male and sixteen female beagle dogs were randomly assigned (4 dogs/sex/group) to the four treatment groups. At the start of the study, the dogs ranged from 8-13 kg in weight and 90 to 98 weeks in age.

iii. Dosage Form: Tablets given once daily.

iv. Placebo Control: Tablets lacking etodolac were given for one year. The number of placebo tablets that were administered was calculated to be the same on a body weight basis as the number of etodolac tablets given to the high dose dogs.

v. Doses Used:

Dose (mg/kg/d)	Relative Dose
0	0X
10	0.7 - 1X
40	2.7 - 4X
80	5.3 - 8X

vi. Route of Administration: Oral.

vii. Treatment Duration: 52 weeks.

viii. Parameters Measured:

- (1) General health observations
- (2) Food consumption
- (3) Body weight
- (4) Physical examination
- (5) Ophthalmoscopic examination
- (6) Electrocardiographic analysis
- (7) Hematology
- (8) Blood chemistry
- (9) Urinalysis
- (10) Gross pathology
- (11) Histopathology

d. Results:

10 mg/kg: Toxicity of etodolac was minimal with adverse reactions being absent or generally mild and transitory and included mild weight loss and fecal alterations (loose or mucoid feces, diarrhea or presence of blood). The most pronounced effect at this dose was a moderate hypoproteinemia (3.6 g/dl) in one dog at four weeks after the start of etodolac treatment. Serum protein concentration in this dog slowly returned toward normal levels during the remainder of the study but remained below normal at study termination (4.9 g/dl). None of the dogs exhibited any gastrointestinal abnormalities upon necropsy.

40 mg/kg: Most of the eight dogs showed some adverse reactions. General effects at this dose included more frequent incidences of emesis and fecal alteration, decreases in erythroid parameters, increases in leukocytic parameters and fibrinogen concentration, and decreases in protein, albumin, and globulin concentration. Intestinal ulceration was present in three dogs at necropsy, and less severe lesions ranging from discoloration to erosion were present in the gastrointestinal tract of four other dogs.

80 mg/kg: The effects of this dose were severe, with a mortality rate of 75% among the eight dogs. All deaths resulted from severe ulcerations to the gastrointestinal tract and included two dogs with perforating lesions and peritonitis. One dog died within 3 weeks of treatment initiation while the other 5 died after 3 to 9 months of daily treatment. All deaths were preceded by body weight loss, frequent episodes of emesis or fecal alteration, decreased food intake, pale mucous membranes, and profound changes in hematological and serum biochemical parameters such as

decreased erythrocyte counts, increased leukocyte and platelet counts, and hypoproteinemia. One of the two surviving dogs at the high dose did not exhibit signs of toxicity, while the other experienced moderate adverse reactions. One dog in the 80 mg/kg group also showed renal tubular nephrosis at necropsy.

No drug-attributable abnormalities were noted in heart rate, electrocardiograms, or ophthalmoscopic observations, and treatment did not alter organ weights at any dosage. The primary toxicological changes following etodolac administration were attributed to gastrointestinal toxicity with changes in hematological and blood biochemical values resulting from the associated blood loss and peritonitis.

e. Conclusions: This study demonstrated that the adverse effects of etodolac given at the minimum use level of 10 mg/kg/day included weight loss, fecal abnormalities and hypoproteinemia. Administration of etodolac at elevated doses of 40 or 80 mg/kg/day once daily for one year caused severe gastrointestinal toxicity, including death at 80 mg/kg/day.

2. AY-24,236: Etodolic Acid Six-Month Oral Toxicity - Dog

a. Type of Study: Six Month Oral Toxicity

b. Investigator: Dr. W. J. Tierney
Bio/dynamics, Inc.
Mettlers Road
East Millstone, NJ 08873

c. General Design

i. Purpose: To determine the toxicological effects of oral doses of etodolac given once daily for six months.

ii. Test Animals: Sixteen male and sixteen female beagle dogs were randomly assigned (4 dogs/sex/group) to the four treatment groups. At the start of the study, the dogs ranged from 8.2-11.3 kg in weight and were 10 months of age.

iii. Dosage Form: Tablets given once daily.

iv. Doses Used:

Dose (mg/kg/d)	Relative Dose
0	0X
15	1 - 1.5X
45	3 - 4.5X
90	6 - 9X

v. Route of Administration: Oral.

vi. Treatment Duration: 26 weeks.

vii. Parameters Measured:

- (1) General health observations
- (2) Food consumption
- (3) Body weight
- (4) Physical examination
- (5) Ophthalmoscopic examination
- (6) Electrocardiographic analysis
- (7) Hematology
- (8) Blood chemistry
- (9) Urinalysis
- (10) Gross pathology
- (11) Histopathology

d. Results:

A dose dependent increase in the incidence of loose, black-tarry, bloody or mucoid stools, and vomiting was observed. Mean body weights in all groups were less than controls with the mean weight of the females in the 90 mg/kg group averaging 10% lower than controls.

15 mg/kg: Toxicological effects on hematological and serum biochemical parameters were absent or small and transitory. Erosions of the intestinal mucosa were described grossly in two dogs but confirmed on histologic examination in only one of the dogs. The other six dogs had less severe gastrointestinal lesions such as mild congestion or hemorrhage.

45 mg/kg: Toxicological reactions at this dose were absent or generally mild. Dogs at this dose experienced decreases in erythroid parameters, increases in leukocytic parameters, and decreases in protein, albumin,

globulin, and bilirubin concentrations. At necropsy, two of the eight dogs exhibited erosions in the small intestine. The other six dogs had less severe gastrointestinal abnormalities such as mild congestion.

90 mg/kg: Adverse reactions at this dose ranged from mild to severe. One of the eight dogs died as the result of an ileal intussusception into the colon, and exhibited many hematological and blood biochemical changes prior to death. Decreases in erythrocyte counts, alanine aminotransferase activity, and protein, albumin, globulin, and bilirubin concentrations, and increases in leukocytic parameters and fibrinogen concentration were mild to severe in all dogs. At necropsy, two of the seven surviving dogs had ulcers in the colon and two others had erosions in the small intestine. The three other surviving dogs had mild abnormalities of the gastrointestinal tract.

e. **Conclusions:** This study demonstrated that etodolac given at 15 mg/kg/day caused erosions in the gastrointestinal tract in one dog when given once daily for up to six months. Administration of etodolac at elevated doses of 45 or 90 mg/kg/day caused more severe gastrointestinal toxicity with ulceration occurring at 90 mg/kg.

3. Study P440-C6

a. **Investigator:** Dr. Peter Schwarz
Department of Veterinary Clinical Sciences
Colorado State University
Fort Collins, CO 80523

b. General Design

- i. **Purpose:** To evaluate the effects of etodolac at doses of approximately 15 mg/kg dose when administered for approximately 9.5 weeks.
- ii. **Test Animals:** Twelve dogs were randomly assigned to etodolac and placebo control treatments (3 dogs/sex/group). Dogs weighed between 24 to 35 kg (53 to 77 lb) at the start of treatment.
- iii. **Placebo Control:** Treatment with tablets similar to the proposed market formulation except for the absence of active ingredient.

- iv. Dosage and Route of Administration: The tablets were identical to the proposed market formulation. Dogs received approximately 15 mg/kg body weight (6.8 mg/lb) orally once daily.
 - v. Disease System: Dogs exhibited normal musculoskeletal condition at the start of the study. Osteoarthritis was induced in the stifle joint by transection of the cranial cruciate ligament in one rear leg. Four weeks later, the stifle joint was stabilized using a modified surgical imbrication technique. The study ended eight weeks after stabilization surgery. Etodolac treatment administration began 10 days prior to stifle stabilization surgery and continued until the end of the study for a duration of 9.5 weeks.
 - vi. Parameters Measured: General health was evaluated by daily, including observations for alertness and evidence of vomiting, diarrhea, or inappetence. Physical examinations were performed at approximately 4 week intervals. Samples for serum chemistry, hematology, urinalysis, and fecal parasite analyses were collected at the time of each physical examination. At the end of the study, all dogs were euthanized and complete necropsies were performed. Any lesions noted on gross necropsy were submitted for histologic evaluation.
- c. Adverse Reactions: Five of six dogs treated with etodolac exhibited excessive hemorrhage during the stifle stabilization surgery compared to two of six control dogs. Instances of diarrhea and vomiting occurred occasionally among dogs receiving etodolac. These instances occurred in the same frequency prior to initiation of etodolac treatment, and with a similar frequency among dogs receiving placebo tablets. Clinico-pathologic analyses did not suggest any adverse drug reactions.
- d. Conclusions: This study evaluated the safety of etodolac administered at a dose of approximately 15 mg/kg/day for 9.5 weeks. The significant adverse effect noted was increased bleeding during surgery in 5 of 6 dogs receiving etodolac treatment, versus 2 of 6 dogs receiving placebo.

VI. Pharmacokinetics and Bioavailability

Studies were conducted in dogs to investigate the pharmacokinetics and bioavailability of etodolac following oral administration. Results of these studies demonstrated that etodolac is rapidly and efficiently absorbed from the gastrointestinal tract.

1. Three-Way Oral Tablet and Oral Gavage Crossover Bioavailability Study with Etodolac in Dogs (P440-C7)

- a. Type of Study: Oral Bioavailability Study
- b. Investigator: Dr. Anthony Kiorpes
Hazleton Wisconsin, Inc.
Madison, WI 53707
- c. General Design
 - i. Purpose: To compare the bioavailability of etodolac when administered as a single oral tablet to fasted and nonfasted dogs and as an oral gavage solution to fasted dogs.
 - ii. Test Animals: Male and female beagles were assigned at random to three treatment groups (3 dogs/sex/group) in a three-way crossover design. Dogs were approximately 5 months old and 7-11 kg in weight at treatment initiation. Fasting was achieved by withholding food overnight until two hours after dose administration.
 - iii. Dosage Form: The tablets were identical to the proposed market formulation. Etodolac in aqueous solution was used for the oral gavage treatment.
 - iv. Doses Used: The dose was approximately 150 mg of etodolac.
 - v. Route of Administration: Oral.
 - vi. Treatment Duration: Single dose.
 - vii. Parameters Measured:
 - (1) Plasma etodolac concentrations
 - (2) General health observations
 - (3) Body weight

d. Results: *Pharmacokinetics in healthy beagle dogs*: Etodolac is rapidly and almost completely absorbed from the gastrointestinal tract following oral administration. The extent of etodolac absorption (AUC) is not affected by the prandial status of the animal. However, it appears that the peak concentration of the drug decreases in the presence of food. As compared to an oral solution, the relative bioavailability of the tablets when given with or without food is essentially 100%. Peak plasma concentrations are usually attained within 2 hours of administration. Though the terminal half-life increases in a nonfasted state, minimal drug accumulation (less than 30 %) is expected after repeated dosing (i.e., at steady-state). Pharmacokinetic parameters estimated in a crossover study (fed vs. fasted) in eighteen 5 month beagle dogs are summarized in the following table:

Table 3. Mean pharmacokinetic parameters estimated in 18 beagle dogs after oral administration of 150 mg of etodolac (approximately 12-17 mg/kg)

Pharmacokinetic parameter	Tablet/Fasted	Tablet/Nonfasted
C _{max} (mg/mL)	22.0 ± 6.42	16.9 ± 8.84
T _{max} (hours)	1.69 ± 0.69	1.08 ± 0.46
AUC _{0-∞} (ug•hours/mL)	64.1 ± 17.9	63.9 ± 28.9
Terminal half-life, t _{1/2} (hrs)	7.66 ± 2.05	11.98 ± 5.52

e. Conclusions: The extent of etodolac absorption (AUC) is not affected by the prandial status of the animal. However, it appears that the peak concentration of the drug decreases in the presence of food.

f. Adverse Reactions: All three etodolac dosing regimens were well tolerated, and all dogs gained weight during the study.

2. Pharmacokinetics in Dogs with Reduced Kidney Function

a. Type of Study: Pharmacokinetics

b. Investigator: Dr. M. Kraml
Ayerst Research Laboratories
Chazy, NY 12921

c. General Design:

- i. Purpose: The study was conducted to determine the pharmacokinetics of etodolac and effects on renal function in dogs in which kidney mass had been surgically reduced by 75%.
 - ii. Test Animals: A total of 12 Beagles weighing 10 to 12 kg body weight were employed in a series of three experiments.
 - iii. Experiments: Four dogs received 200 mg of etodolac daily for five days before and after surgical reduction of kidney mass. Four dogs received a single dose of 200 mg of etodolac before and after surgical reduction of kidney mass. In 4 dogs with reduced kidney mass, clearance of *p*-aminohippurate before or one hour after a single dose of 200 mg of etodolac was measured.
 - iv. Dosage Form: Etodolac powder.
 - v. Route of Administration: Oral.
 - vi. Treatment Duration: Single oral doses up to 5 days.
 - viii. Parameters Measured: Concentrations of etodolac in the serum, hematological and blood biochemical determinations, and urinalysis.
- d. Results: In the first experiment, four dogs were administered an etodolac regimen of five daily doses before and after surgical reduction of kidney mass. Etodolac bioavailability as measured by area under the concentration by time curve (AUC) was unaffected. This finding was expected due to the low contribution of urinary excretion to elimination of etodolac in normal dogs.

In the second experiment, renal function in dogs with reduced kidney mass was studied before and after a single administration of etodolac. Etodolac treatment had no effect on serum albumin or total protein concentrations, or urine volume. Similarly, excretion of potassium, sodium, chloride, or creatinine were unaffected.

A third experiment, using dogs with reduced kidney mass, measured the clearance of *p*-aminohippurate before or one hour after a single

dose of etodolac. Clearance of *p*-aminohippurate was unaffected by etodolac treatment.

- e. Conclusions: In a study involving four beagle dogs with induced acute renal failure, there was no observed change in drug bioavailability after administration of 200 mg single oral etodolac doses. In a study evaluating an additional four beagles, no changes in electrolyte, serum albumin/total protein and creatinine concentrations were observed after single 200 mg doses of etodolac. This was not unexpected since very little etodolac is cleared by the kidneys in normal animals. Most of etodolac and its metabolites are eliminated via the liver and feces. In addition, etodolac is believed to undergo enterohepatic recirculation. (See Cayen, M.N., M. Kraml, E.S. Ferdinandi, El Greselin, D. Dvornik. The Metabolic Disposition of Etodolac in Rats, Dogs, and Man. *Drug Metab. Revs.* (1981) 12: 339-362.)

VII. Human Safety

Data on human food safety, pertaining to consumption of drug residues in food, were not required for approval of this NADA. The drug is to be labeled for use in dogs, which are non-food animals.

Human Safety Relative to Possession, Handling, and Administration:

Labeling contains adequate warning statements relative to user safety.

VIII. Agency Conclusions

Data in support of this NADA comply with the requirements of Section 512 of the Act and Section 514.111 of the implementing regulations. The data demonstrate that EtoGesic™ (etodolac), when used according to labeled conditions, is safe and effective.

EtoGesic™ is restricted to use by or on the order of a licensed veterinarian because professional veterinary expertise is required to determine when a dog has a condition such as osteoarthritis, and to monitor the dog for signs of adverse reactions.

Under Section 512(c)(2)(F)(i) of the Federal Food, Drug, and Cosmetic Act, this approval qualifies for five years of marketing exclusivity beginning on the date of

approval because no active ingredient, including any ester or salt of the active ingredient, of the drug has been approved in any other application.

IX. Labeling (attached)

package insert
bottle label 100 count, 150 mg
bottle label 250 count, 150 mg
bottle label 100 count, 300 mg
bottle label 250 count, 300 mg

FORT DODGE


EtoGesic[™] (etodolac)

TABLETS FOR ORAL USE IN DOGS ONLY

Caution: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

Etodolac is a pyranocarboxylic acid, chemically designated as (±) 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b] indole-1-acetic acid. The structural formula for etodolac is shown:



The empirical formula for etodolac is $C_{21}H_{25}NO_3$. The molecular weight of the base is 287.37. It has a pKa of 4.65 and an *n*-octanol/water partition coefficient of 11.4 at pH 7.4. Etodolac is a white crystalline compound, insoluble in water but soluble in alcohols, chloroform, dimethyl sulfoxide, and aqueous polyethylene glycol. Each tablet is biconvex and half-scored and contains either 150 or 300 mg of etodolac.

HOW SUPPLIED

EtoGesic (etodolac) is available in 150 and 300 mg single-scored tablets and supplied in bottles containing 100 and 250 tablets.

NDC 0856-5520-01 - 150 mg - bottles of 100
NDC 0856-5520-02 - 150 mg - bottles of 250
NDC 0856-5530-01 - 300 mg - bottles of 100
NDC 0856-5530-02 - 300 mg - bottles of 250

STORAGE CONDITIONS

Store at controlled room temperature, 15-30°C (59-86°F).

INDICATIONS

EtoGesic is recommended for the management of pain and inflammation associated with osteoarthritis in dogs.

DOSEAGE AND ADMINISTRATION

The recommended dose of etodolac in dogs is 10 to 15 mg/kg body weight (4.5 to 6.8 mg/lb) administered once daily. Due to tablet sizes and scoring, dogs weighing less than 5 kg (11 lb) cannot be accurately dosed. The effective dose and duration should be based on clinical judgment of disease condition and patient tolerance of drug treatment. The initial dose level should be adjusted until a satisfactory clinical response is obtained, but should not exceed 15 mg/kg once daily. When a satisfactory clinical response is obtained, the daily dose level should be reduced to the minimum effective dose for longer term administration.

CONTRAINDICATIONS

EtoGesic is contraindicated in animals previously found to be hypersensitive to etodolac.

HUMAN WARNINGS

For use in animals only. Keep out of reach of children.

ADVERSE REACTIONS

In a placebo-controlled clinical field trial involving 116 dogs, where treatment was administered for 8 days, the following adverse reactions were noted:

Adverse Reaction	EtoGesic Tablets % of Dogs	Placebo % of Dogs
vomiting	4.3%	1.7%
regurgitation	0.9%	2.6%
lethargy	3.4%	2.6%
diarrhea/loose stool	2.6%	1.7%
hypoproteinemia	2.6%	0
urticaria	0.9%	0
behavioral change, urinating in house	0.9%	0
inappetence	0.9%	1.7%

Following completion of the clinical field trial, 92 dogs continued to receive etodolac. One dog developed diarrhea following 2-1/2 weeks of treatment. Etodolac was discontinued until resolution of clinical signs was observed. When treatment was resumed, the diarrhea returned within 24 hours. One dog experienced vomiting which was attributed to treatment, and etodolac was discontinued. Hypoproteinemia was identified in one dog following 11 months of etodolac therapy. Treatment was discontinued, and serum protein levels subsequently returned to normal.

To report suspected adverse reactions, or to obtain technical assistance, call (800) 477-1365.

PRECAUTIONS

Treatment with EtoGesic tablets should be terminated if signs such as inappetence, emesis, fecal abnormalities, or anemia are observed. Dogs treated with nonsteroidal anti-inflammatory drugs, including etodolac, should be evaluated periodically to ensure that the drug is still necessary and well tolerated. Owners should be advised to observe for signs of potential drug toxicity.

EtoGesic, as with other nonsteroidal anti-inflammatory drugs, may exacerbate clinical signs in dogs with pre-existing or occult gastrointestinal, hepatic or cardiovascular abnormalities, blood dyscrasias, or bleeding disorders.

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal and renal toxicity. Sensitivity to drug-associated adverse effects varies with the individual patient. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction. Since many NSAIDs possess the potential to induce gastrointestinal ulceration, concomitant use of etodolac with other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided or closely monitored.

Studies to determine the activity of EtoGesic tablets when administered concomitantly with other protein-bound drugs have not been conducted in dogs. Drug compatibility should be monitored closely in patients requiring adjunctive therapy.

The safety of EtoGesic has not been investigated in breeding, pregnant or lactating dogs or in dogs under 12 months of age.

PHARMACOLOGY

Etodolac is a non-narcotic, nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, anti-pyretic, and analgesic activity. The mechanism of action of etodolac, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals^{1,2}. The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity, while inhibition of COX-2 provides anti-inflammatory activity. In *in vitro* experiments, etodolac demonstrated more selective inhibition of COX-2 than COX-1³. Etodolac also inhibits macrophage chemotaxis *in vivo* and *in vitro*⁴. Because of the importance of macrophages in the inflammatory response, the anti-inflammatory effect of etodolac could be partially mediated through inhibition of the chemotactic ability of macrophages.

Pharmacokinetics in healthy beagle dogs: Etodolac is rapidly and almost completely absorbed from the gastrointestinal tract following oral administration. The extent of etodolac absorption (AUC) is not affected by the prandial status of the animal. However, it appears that the peak concentration of the drug decreases in the presence of food. As compared to an oral solution, the relative bioavailability of the tablets when given with or without food is essentially 100%. Peak plasma concentrations are usually attained within 2 hours of administration. Though the terminal half-life increases in a nonfasted state, minimal drug accumulation (less than 30%) is expected after repeated dosing (i.e., steady-state). Pharmacokinetic parameters estimated in a crossover study (fed vs. fasted) in eighteen 5-month old beagle dogs are summarized in the following table:

Mean Pharmacokinetic Parameters Estimated in 18 Beagle Dogs After Oral Administration of 150 mg of Etodolac (approximately 12-17 mg/kg)

Pharmacokinetic Parameter	Tablet/ Fasted	Tablet/ Nonfasted
C_{max} (µg/mL)	22.0±6.42	16.9±8.84
T_{max} (hours)	1.69±0.69	1.08±0.46
$AUC_{0-\infty}$ (µg·hours/mL)	64.1±17.9	63.9±28.9
Terminal half-life, $t_{1/2}$ (hrs)	7.66±2.05	11.98±5.52

Pharmacokinetics in dogs with reduced kidney function: In a study involving four beagle dogs with induced acute renal failure, there was no observed change in drug bioavailability after administration of 200 mg single oral etodolac doses. In a study evaluating an additional four beagles, no changes in electrolyte, serum albumin/total protein and creatinine concentrations were observed after single 200 mg doses of etodolac. This was not unexpected since very little etodolac is cleared by the kidneys in normal animals. Most of etodolac and its metabolites are eliminated via the liver and feces. In addition, etodolac is believed to undergo enterohepatic recirculation⁵.

EFFICACY

A placebo-controlled, double-blinded study demonstrated the anti-inflammatory and analgesic efficacy of EtoGesic (etodolac) tablets in various breeds of dogs. In this clinical field study, dogs diagnosed with osteoarthritis secondary to hip dysplasia showed objective improvement in mobility as measured by force plate parameters when given EtoGesic tablets at the label dosage for 8 days.

SAFETY

In target animal safety studies, etodolac was well tolerated clinically when given at the label dosage for periods as long as one year (see Precautions).

Oral administration of etodolac at a daily dosage of 10 mg/kg (4.5 mg/lb) for twelve months or 15 mg/kg (6.8 mg/lb) for six months, resulted in some dogs showing a mild weight loss, fecal abnormalities (loose, mucoid, mucosanguineous feces or diarrhea), and hypoproteinemia. Erosions in the small intestine were observed in one of the eight dogs receiving 15 mg/kg following six months of daily dosing.

Elevated dose levels of EtoGesic (etodolac), i.e. ≥40 mg/kg/day (18 mg/lb/day, 2.7X the maximum daily dose), caused gastrointestinal ulceration, anorexia, fecal occult blood, and weight loss. At a dose of ≥80 mg/kg/day (36 mg/lb/day, 5.3X the maximum daily dose), 6 of 8 treated dogs died or became moribund as a result of gastrointestinal ulceration. One dog died within 3 weeks of treatment initiation while the other 5 died after 3-9 months of daily treatment. Deaths were preceded by clinical signs of anorexia, fecal abnormalities, decreased food intake, weight loss, and pale mucous membranes. Renal tubular nephrosis was also found in 1 dog treated with 80 mg/kg for 12 months. Other common abnormalities observed at elevated doses included reductions in red blood cell count, hemoglobin, hemoglobin, total protein and albumin concentrations; and increases in fibrinogen concentration and reticulocyte, leukocyte, and platelet counts.

In an additional study which evaluated the effects of etodolac administered to 6 dogs at the labeled dose for approximately 9.5 weeks, the incidence of stool abnormalities (diarrhea, loose stools) was unchanged for dogs in the weeks prior to initiation of etodolac treatment, and during the course of etodolac therapy. Five of the dogs receiving etodolac, versus 2 of the placebo-treated dogs, exhibited excessive bleeding during an experimental surgery. No significant evidence of drug-related toxicity was noted on necropsy.

REFERENCES

- Vane, J.R. RM Botting. Overview - mechanisms of action of anti-inflammatory drugs, in *Improved Non-steroid Anti-inflammatory Drugs: COX-2 Enzyme Inhibitors*. J Vane, J Botting, R Botting (ed.) 1996. Kluwer Academic Publishers, Dordrecht, The Netherlands.
- Glaser, KB. Cyclooxygenase selectivity and NSAIDs: cyclooxygenase-2 selectivity of etodolac (Lodine[®]). *Inflammopharmacol* (1995) 3:335-345.
- Gervais, F, RR Mantel, E Skarnens. The effect of the non-steroidal anti-inflammatory drug etodolac on macrophage migration *in vitro* and *in vivo*. *J Immunopharmacol* (1994) 6:205-214.
- Cayen, MN, M Kraml, ES Ferdinandi, EL Gresslin, D Dvornik. The metabolic disposition of etodolac in rats, dogs, and man. *Drug Metab. Revs* (1981) 12:339-362.

Fort Dodge Animal Health
Fort Dodge, Iowa 50501 USA

5530A

New July 1996

91918

NDC 0856-5520-01

EtoGesic™
(etodolac)



FORT DODGE®

FOR ORAL USE IN DOGS ONLY

150 mg

100 TABLETS

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
NADA 141-108, Approved by FDA

INDICATIONS: EtoGesic (etodolac) is recommended for the management of pain and inflammation associated with osteoarthritis in dogs.
DOSAGE AND ADMINISTRATION: The recommended dose of etodolac in dogs is 10 to 15 mg/kg body weight (4.5 to 6.8 mg/lb) administered once daily. Read package insert before use.
HUMAN WARNINGS: For use in animals only. Keep out of reach of children.

Store at controlled room temperature, 15° to 30° C (59° to 86° F).

Fort Dodge Animal Health
Fort Dodge, Iowa 50501 USA

Lot
Exp. Date

5523A

40552310

NDC 0856-5520-02

EtoGesic™
(etodolac)



FORT DODGE®

FOR ORAL USE IN DOGS ONLY

150 mg

250 TABLETS

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

NADA 141-108, Approved by FDA

INDICATIONS: EtoGesic (etodolac) is recommended for the management of pain and inflammation associated with osteoarthritis in dogs.

DOSAGE AND ADMINISTRATION: The recommended dose of etodolac in dogs is 10 to 15 mg/kg body weight (4.5 to 6.8 mg/lb) administered once daily. Read package insert before use.

HUMAN WARNINGS: For use in animals only. Keep out of reach of children.

Store at controlled room temperature, 15° to 30°C (59° to 86°F).

Fort Dodge Animal Health
Fort Dodge, Iowa 50501 USA

Lot
Exp. Date

5524A

NDC 0856-5530-01

EtoGesic™
(etodolac)



FORT DODGE®

FOR ORAL USE IN DOGS ONLY

300 mg

100 TABLETS

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

NADA 141-108, Approved by FDA

INDICATIONS: EtoGesic (etodolac) is recommended for the management of pain and inflammation associated with osteoarthritis in dogs.

DOSAGE AND ADMINISTRATION: The recommended dose of etodolac in dogs is 10 to 15 mg/kg body weight (4.5 to 6.8 mg/lb) administered once daily. Read package insert before use.

HUMAN WARNINGS: For use in animals only. Keep out of reach of children.

Store at controlled room temperature, 15° to 30°C (59° to 86°F).

Fort Dodge Animal Health
Fort Dodge, Iowa 50501 USA

Lot
Exp. Date

5533A

NDC 0856-5530-02

EtoGesic™
(etodolac)



FORT DODGE®

FOR ORAL USE IN DOGS ONLY

300 mg

250 TABLETS

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

NADA 141-108, Approved by FDA

INDICATIONS: EtoGesic (etodolac) is recommended for the management of pain and inflammation associated with osteoarthritis in dogs.

DOSAGE AND ADMINISTRATION: The recommended dose of etodolac in dogs is 10 to 15 mg/kg body weight (4.5 to 6.8 mg/lb) administered once daily. Read package insert before use.

HUMAN WARNINGS: For use in animals only. Keep out of reach of children.

Store at controlled room temperature, 15° to 30°C (59° to 86°F).

Fort Dodge Animal Health
Fort Dodge, Iowa 50501 USA

Lot
Exp. Date

5534